Korea United Pharm. Inc.

Quick facts

Marketed products

• Cefecin Tab.
• Omnicef Cap. · Infectious Disease
  Omnicef (cefdinir) is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.

Phase 3 pipeline

• KALOMIN™ Tab. · Electrolyte/Metabolic Disorders
  KALOMIN is a potassium supplement that replaces depleted electrolytes to restore normal serum potassium levels.
• UI05MSP015CT · Diabetes
  This drug is a small molecule that targets the SGLT2 receptor.
• Umckamin syrup · Respiratory / Immunology
  Umckamin is an herbal extract that enhances immune function and reduces inflammation to help the body fight respiratory infections.

Phase 2 pipeline

• UI030

Phase 1 pipeline

• administration of UI018
• administration of UI058
• administration of UI068
• administration of UIC202004
• administration of UIC202205, UIC202206
• Anplag · Other
• UI009
• UI03SPG300CT
• UI059
• UI15AML055MT
• UIC201602 and co-administration of UIC201601 and UIC201602
• UIC202005
• UIC202201

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Korea United Pharm. Inc. portfolio CI brief
• Korea United Pharm. Inc. pipeline updates RSS